Medical School, University of Geneva, Rue Michel-Servet 1, 1206, Geneva, Switzerland.
Cambridge Colorectal Unit, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Tech Coloproctol. 2023 Nov;27(11):979-993. doi: 10.1007/s10151-023-02853-8. Epub 2023 Aug 26.
Complete mesocolic excision improves lymphadenectomy for right hemicolectomy and respects the embryological planes. However, its effect on cancer-free and overall survival is questioned. Therefore, we aimed to determine the potential benefits of the technique by performing a systematic review of the literature and meta-analysis of the available evidence.
Web of Science, PubMed/Medline, and Embase were searched on February 22, 2023. Original studies on short- and long-term oncological outcomes of adult patients undergoing right hemicolectomy with complete mesocolic excision as a treatment for primary colon cancer were considered for inclusion. Outcomes were extracted and pooled using a model with random effects.
A total of 586 publications were identified through database searching, and 18 from citation searching. Exclusion of 552 articles left 24 articles for inclusion. Meta-analysis showed that complete mesocolic excision increased the lymph node harvest (5 studies, 1479 patients, MD 9.62, 95% CI 5.83-13.41, p > 0.0001, I 84%), 5-year overall survival (5 studies, 2381 patients, OR 1.88, 95% CI 1.14-3.09, p = 0.01, I 66%), 5-year disease-free survival (4 studies, 1376 patients, OR 2.21, 95% CI 1.51-3.23, p < 0.0001, I 0%) and decreased the incidence of local recurrence (4 studies, 818 patients, OR 0.27, 95% CI 0.09-0.79, p = 0.02, I 0%) when compared to standard right hemicolectomy. Perioperative morbidity was similar between the techniques (8 studies, 3899 patients, OR 1.04, 95% CI 0.89-1.22, p = 0.97, I 0%).
Meta-analysis of observational and randomised studies showed that right hemicolectomy with complete mesocolic excision for primary right colon cancer improves oncologic results without increasing morbidity/mortality. These results need to be confirmed by high-quality evidence and randomised trials in selected patients to assess who may benefit from the procedure.
完整结肠系膜切除术可提高右半结肠切除术的淋巴结清扫效果,并尊重胚胎学平面。然而,其对无癌和总生存的影响仍存在争议。因此,我们旨在通过系统回顾文献和荟萃分析现有证据来确定该技术的潜在益处。
于 2023 年 2 月 22 日检索 Web of Science、PubMed/Medline 和 Embase 数据库,纳入有关接受完整结肠系膜切除术治疗原发性结肠癌的成年患者的短期和长期肿瘤学结局的原始研究。使用具有随机效应的模型提取和汇总结果。
通过数据库搜索共确定了 586 篇文献,通过引文搜索确定了 18 篇文献。排除 552 篇文章后,纳入 24 篇文章。荟萃分析显示,完整结肠系膜切除术增加了淋巴结清扫(5 项研究,1479 例患者,MD9.62,95%CI5.83-13.41,p>0.0001,I²84%)、5 年总生存率(5 项研究,2381 例患者,OR1.88,95%CI1.14-3.09,p=0.01,I²66%)、5 年无病生存率(4 项研究,1376 例患者,OR2.21,95%CI1.51-3.23,p<0.0001,I²0%)和降低局部复发率(4 项研究,818 例患者,OR0.27,95%CI0.09-0.79,p=0.02,I²0%),与标准右半结肠切除术相比。两种技术的围手术期发病率相似(8 项研究,3899 例患者,OR1.04,95%CI0.89-1.22,p=0.97,I²0%)。
观察性和随机研究的荟萃分析表明,原发性右半结肠癌的完整结肠系膜切除术可改善肿瘤学结果,而不会增加发病率/死亡率。这些结果需要通过高质量的证据和在选定患者中进行的随机试验来证实,以评估谁可能从该手术中受益。